KKR partners with LGC to facilitate future expansion and growth

Published: 10-Dec-2015
Regulatory Finance

Will provide capital and operational support to facilitate future growth


Private equity firm KKR has agreed to buy life sciences measurement and testing firm LGC from London-based investment group Bridgepoint, for an undisclosed sum.

KKR will provide capital and operational support to facilitate future growth.

London-headquartered LGC said under the ownership of KKR it plans to 'continue the rapid development of the business', with a particular focus on the US and Asia. The company provides measurement products and services, including reference materials and proficiency testing, genomics reagents, instrumentation and services, and expert sample analysis and interpretation to customers in the pharmaceuticals, agricultural biotechnology, food, environment, government and academia sectors.

Tim Robinson, CEO, LGC said: 'We have ongoing, exciting growth opportunities across our entire business that will strengthen our solutions to our existing customers and help us expand into new markets and geographies. This is an exciting new phase in LGC's development and we believe that KKR’s network, market knowledge and support make them an ideal, new partner for our business.'

KKR said its global network, 'as well as its experience and deep relationships in the life sciences and healthcare sectors', will help LGC to grow.

  • Companies:
  • LGC Group
See more

You may also like

Finance

LGC acquires NGS kit supplier

Read more
Rapid Genomics provides kits to help enable the development of more productive and resilient plants and animals

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  4. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Finance

LGC acquires NGS kit supplier

Rapid Genomics provides kits to help enable the development of more productive and resilient plants and animals
Regulatory

LGC SARS-CoV-2 testing system granted emergency use authorisation

The FDA’s authorisation enables qualified laboratories to address testing demands while providing significant economic advantage, LGC says
Finance

LGC acquires Paragon Scientific

Founded in 1994, Paragon employs 22 people in the North West of England with two facilities located in Birkenhead and is accredited to ISO 17025 and ISO 17034
Finance

LGC acquires Technopath Clinical Diagnostics

The move is aimed to strengthen LGC's clinical quality controls
Finance

LGC acquires MBH Analytical

LGC has announced that it has acquired MBH Analytical (MBH) a leading manufacturer of metal alloy reference materials (RMs)
Regulatory

LGC acquires Axolabs and invests in GMP manufacturing capacity for TNAs

LGC announced that it has acquired Axolabs, a leading Contract Research, Development and Manufacturing Organisation, specialising in the development of therapeutic nucleic acids (TNAs)
Regulatory

LGC accelerates the development of new medicines

As regulatory pressure increases companies are saving time and money with effective extractables and leachables programmes
Subscribe now